Curt I Civin

USPTO Granted Patents = 24 (Patent Applications = 15)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.5

ph-index = 11

Forward Citations = 687(Granted Patents)

Location History:

Towson, MD (US) (2010)
Baltimore, MD (US) (1987 - 2023)

Company Filing History:

13 out of 1,929

University System of Maryland

patents

11 out of 3,687

Johns Hopkins University

Becton Dickinson and Company Limited

patents

6. 1 out of 2,597

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 1987-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12436081 - Methods and devices for multi-step cell purification and concentration (2025-10-07),

2. 11554105 - Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment (2023-01-17),

3. 11493428 - On-chip microfluidic processing of particles (2022-11-08),

4. 11486802 - Methods and devices for high throughput purification (2022-11-01),

5. 11306288 - Methods for preparing therapeutically active cells using microfluidics (2022-04-19),

6. 11149251 - Methods for preparing therapeutically active cells using microfluidics (2021-10-19),

7. 11142746 - High efficiency microfluidic purification of stem cells to improve transplants (2021-10-12),

8. 10988734 - Methods for preparing therapeutically active cells using microfluidics (2021-04-27),

9. 10976232 - Methods and devices for multi-step cell purification and concentration (2021-04-13),

10. 10852220 - Methods and devices for high throughput purification (2020-12-01),

11. 10844353 - Methods for preparing therapeutically active cells using microfluidics (2020-11-24),

12. 10324011 - Methods and devices for high throughput purification (2019-06-18),

13. 9918972 - Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents (2018-03-20),

14. 7799528 - Therapeutic and diagnostic applications of genes differentially expressed in lympho-hematopoietic stem cells (2010-09-21),

15. 7767202 - Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules (2010-08-03),

Title: Curt I Civin: A Pioneer in Cancer Treatment Innovations

Introduction

Curt I Civin is a notable inventor and researcher based in Baltimore, MD, USA. With a prolific output of 23 patents, he has made significant contributions to the fields of cancer treatment and microfluidic technology, solidifying his reputation as a leader in innovation.

Latest Patents

Civin's latest patents focus on groundbreaking methods for treating cancer, particularly leukemia. One of his notable inventions involves the use of combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors. The detailed methods showcase how therapeutic amounts of artemisinins, such as artesunate and dihydroartemisinin, can be administered alongside additional agents like BCL-2 inhibitors (e.g., ABT-199) and various kinase inhibitors to enhance treatment efficacy. Furthermore, his work on microfluidic processing devices reveals techniques and systems designed to improve cell quality, streamline workflows, and reduce costs in research and clinical diagnostics for various diseases.

Career Highlights

Civin’s career includes pivotal roles at prestigious institutions such as the University of Maryland and Princeton University. His research work has led to innovative solutions in cancer therapy and biotechnology, establishing him as a key figure in his field. His inventive strategies are crucial for advancing cancer treatment methodologies.

Collaborations

Throughout his career, Curt I Civin has collaborated with esteemed colleagues, including James Christopher Sturm and Robert H. Austin. These partnerships have fostered innovation, enabling the development and refinement of new approaches in cancer treatment and diagnostics.

Conclusion

Curt I Civin's contributions to medical innovation, particularly in cancer treatment and microfluidic technology, highlight his role as a leading inventor. His extensive patent portfolio reflects a commitment to enhancing treatment options and improving clinical outcomes, illustrating the vital impact he has made on science and medicine.

This text is generated by artificial intelligence and may not be accurate.